Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.50 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208332 | 0.85 | DYRK1A (0.48) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL21083379 | 0.79 | TGFBR1 (0.52) | TGFBR1KDM4EHPGDHSD17B10FYN | |
| SCHEMBL24771760 | 0.77 | DYRK1A (0.46) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL14881524 | 0.76 | PIM1 (0.43) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL12850753 | 0.76 | TNF (0.51) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL23872989 | 0.75 | GRN (0.45) | CDK5TGFBR1KDM4EFYN | |
| SCHEMBL2903376 | 0.74 | FYN (0.71) | FYN | |
| SCHEMBL2906009 | 0.74 | FYN (0.51) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL14881554 | 0.74 | TGFBR1 (0.35) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 | |
| SCHEMBL15973521 | 0.73 | DYRK1A (0.51) | DYRK1ADYRK3DYRK2DYRK1BCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | DYRK1A 4464/4885DYRK3 4514/4885DYRK2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.